Finch Therapeutics Group is a clinical-stage microbiome therapeutics company utilizing its Human-First Discovery platform to develop a class of orally administered biological drugs. Co. is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Co.'s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Co.'s primary product candidate, CP101, is an orally administered microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection. The FNCH stock yearly return is shown above.
The yearly return on the FNCH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FNCH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|